Epitalonacetat CAS:307297-40-1

Epithalon was first discovered in the late 1980's by Prof. Vladimir Khavinson from St. Petersburg, Russia. It has been studied extensively ever since. It is known by several names, including Epitalon, Epithalon, Epithalone, Epithalamin and Epithalamine. Since all the patents are held by the Russian inventor there is not much interest for this tetra-peptide from the western big pharma industry. This makes the substance fairly unknown in the west due to the absence of marketing usually seen with big pharma products. In Russia it is currently in clinical studies and shows prospective results as treatment for liver disorders, neuropathology, psychiatry and geriatrics.

Epitalon decreases the age-related changes in immune and neuroendocrine systems, reduces the incidence of recurrent infections and chronic diseases. Long term clinical trials have shown that in patients with age-related pathology Epithalamin eliminates imbalance in prooxidation and antioxidation systems. Results of 12-months treatment with Epithalon in patients with signs of accelerated aging showed normalizing effect on metabolism and condition of various functional systems. Elevated uric acid, alkaline phosphatase and cholesterol in elder patients returned to normal after 10 days of treatment, and remained stable in a several months peroid afterwards.